Yang Chen1,2, Gail J Harty1, Ye Zheng1, Seethalakshmi R Iyer1, Shinobu Sugihara1, S Jeson Sangaralingham1,3, Tomoko Ichiki1, Joseph P Grande4, Hon-Chi Lee5, Xiaoli Wang5, John C Burnett1,3. 1. From the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN. 2. Mayo Clinic Graduate School of Biomedical Sciences (Y.C.), Mayo Clinic, Rochester, MN. 3. Department of Physiology and Biomedical Engineering (S.J.S., J.C.B.), Mayo Clinic, Rochester, MN. 4. Department of Laboratory Medicine and Pathology (J.P.G.), Mayo Clinic, Rochester, MN. 5. Department of Cardiovascular Medicine (H.-C.L., X.L.W.), Mayo Clinic, Rochester, MN.
Abstract
RATIONALE: Acute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential. OBJECTIVE: We investigated the therapeutic potential of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large animal model of ischemia-induced AKI and also investigated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI. METHODS AND RESULTS: We first showed that CRRL269 stimulated cGMP generation, suppressed plasma angiotensin II, and reduced cardiac filling pressures without lowering blood pressure in the AKI canine model. We also demonstrated that CRRL269 preserved glomerular filtration rate, increased renal blood flow, and promoted diuresis and natriuresis. Further, CRRL269 reduced kidney injury and apoptosis as evidenced by ex vivo histology and tissue apoptosis analysis. We also showed, compared with native pGC-A activators, that CRRL269 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular Ca2+ concentration in vascular smooth muscle cells. The renal antiapoptotic effects were at least mediated by cGMP/PKG pathway. Further, CRRL269 inhibited proapoptotic genes expression using a polymerase chain reaction gene array. Additionally, we demonstrated that AKI increased uCNP levels. CONCLUSIONS: Our study supports developing CRRL269 as a novel renocardiac protective agent for AKI treatment.
RATIONALE: Acute kidney injury (AKI) has a high prevalence and mortality in critically illpatients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential. OBJECTIVE: We investigated the therapeutic potential of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large animal model of ischemia-induced AKI and also investigated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI. METHODS AND RESULTS: We first showed that CRRL269 stimulated cGMP generation, suppressed plasma angiotensin II, and reduced cardiac filling pressures without lowering blood pressure in the AKI canine model. We also demonstrated that CRRL269 preserved glomerular filtration rate, increased renal blood flow, and promoted diuresis and natriuresis. Further, CRRL269 reduced kidney injury and apoptosis as evidenced by ex vivo histology and tissue apoptosis analysis. We also showed, compared with native pGC-A activators, that CRRL269 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular Ca2+ concentration in vascular smooth muscle cells. The renal antiapoptotic effects were at least mediated by cGMP/PKG pathway. Further, CRRL269 inhibited proapoptotic genes expression using a polymerase chain reaction gene array. Additionally, we demonstrated that AKI increased uCNP levels. CONCLUSIONS: Our study supports developing CRRL269 as a novel renocardiac protective agent for AKI treatment.
Authors: S Jeson Sangaralingham; Denise M Heublein; Joseph P Grande; Alessandro Cataliotti; Andrew D Rule; Paul M McKie; Fernando L Martin; John C Burnett Journal: Am J Physiol Renal Physiol Date: 2011-08-24
Authors: Peter A McCullough; John A Kellum; Michael Haase; Christian Müller; Kevin Damman; Patrick T Murray; Dinna Cruz; Andrew A House; Kai M Schmidt-Ott; Giorgio Vescovo; Sean M Bagshaw; Eric A Hoste; Carlos Briguori; Branko Braam; Lakhmir S Chawla; Maria R Costanzo; James A Tumlin; Charles A Herzog; Ravindra L Mehta; Hamid Rabb; Andrew D Shaw; Kai Singbartl; Claudio Ronco Journal: Contrib Nephrol Date: 2013-05-13 Impact factor: 1.580
Authors: Yang Chen; Jacob J Schaefer; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; S Jeson Sangaralingham; Horng H Chen; Margaret M Redfield; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2020-02-05 Impact factor: 3.619
Authors: Feby Savira; Ruth Magaye; Danny Liew; Christopher Reid; Darren J Kelly; Andrew R Kompa; S Jeson Sangaralingham; John C Burnett; David Kaye; Bing H Wang Journal: Br J Pharmacol Date: 2020-05-13 Impact factor: 8.739
Authors: Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham Journal: JACC Heart Fail Date: 2021-07-07 Impact factor: 12.544
Authors: Balamurugan Packialakshmi; Ian J Stewart; David M Burmeister; Kevin K Chung; Xiaoming Zhou Journal: Ren Fail Date: 2020-11 Impact factor: 2.606